Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.10), $0.07 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $17.69 million versus the consensus estimate of $18 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.